Published in J Matern Fetal Neonatal Med on August 09, 2011
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05
Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension (2012) 0.97
New developments in the pathogenesis of preeclampsia. Adv Chronic Kidney Dis (2013) 0.97
Early prediction of preeclampsia. Obstet Gynecol Int (2014) 0.95
Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One (2012) 0.94
Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol (2015) 0.88
Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth (2013) 0.88
Cost and resource implications with serum angiogenic factor estimation in the triage of pre-eclampsia. BJOG (2013) 0.88
Evidence of an imbalance of angiogenic/antiangiogenic factors in massive perivillous fibrin deposition (maternal floor infarction): a placental lesion associated with recurrent miscarriage and fetal death. Am J Obstet Gynecol (2013) 0.87
Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J Matern Fetal Neonatal Med (2013) 0.87
Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One (2012) 0.85
In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80
Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa. J Perinat Med (2013) 0.80
Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens (2013) 0.79
Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med (2013) 0.79
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78
Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn (2015) 0.78
Role of Extracellular Vesicles and microRNAs on Dysfunctional Angiogenesis during Preeclamptic Pregnancies. Front Physiol (2016) 0.78
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One (2015) 0.77
Endoglin in amniotic fluid as a risk factor for the subsequent development of bronchopulmonary dysplasia. Am J Reprod Immunol (2012) 0.77
Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks' Gestation: A Budget Impact Analysis. PLoS One (2016) 0.75
Pathophysiology of preeclampsia: an angiogenic imbalance and long-lasting systemic vascular dysfunction. Hypertens Res (2016) 0.75
Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review. Hypertension (2017) 0.75
The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study. PLoS One (2017) 0.75
WHO analysis of causes of maternal death: a systematic review. Lancet (2006) 20.24
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
A United States national reference for fetal growth. Obstet Gynecol (1996) 13.21
Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem (1998) 8.30
Latest advances in understanding preeclampsia. Science (2005) 8.11
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest (2003) 6.44
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol (1999) 4.74
Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med (2006) 4.27
Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ (2001) 4.24
Trial of calcium to prevent preeclampsia. N Engl J Med (1997) 3.69
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis (2007) 3.47
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet (2002) 3.38
Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem (2003) 3.36
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet (2010) 3.15
Preeclampsia: recent insights. Hypertension (2005) 2.98
Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med (1993) 2.96
Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med (1998) 2.90
Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology (2004) 2.83
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
A meta-analysis of low-dose aspirin for the prevention of pregnancy-induced hypertensive disease. JAMA (1991) 2.77
Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol (2004) 2.72
Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol (1998) 2.71
Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol (2011) 2.66
Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. Am J Obstet Gynecol (1997) 2.66
Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension (2009) 2.51
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol (2010) 2.43
Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ (2008) 2.21
A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod (1998) 2.12
Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol (2006) 2.10
Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab (2003) 2.07
Identification of severe maternal morbidity during delivery hospitalizations, United States, 1991-2003. Am J Obstet Gynecol (2008) 2.05
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol (2009) 1.92
An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol (2010) 1.90
Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem (2005) 1.89
Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab (2003) 1.88
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol (1998) 1.79
Shared constitutional risks for maternal vascular-related pregnancy complications and future cardiovascular disease. Hypertension (2008) 1.77
The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med (1989) 1.75
Overview of maternal morbidity during hospitalization for labor and delivery in the United States: 1993-1997 and 2001-2005. Obstet Gynecol (2009) 1.72
Adverse perinatal outcomes are significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol (2002) 1.70
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks' gestation. Am J Obstet Gynecol (2000) 1.61
Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension (2008) 1.61
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol (1996) 1.57
Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis. Am J Pathol (2001) 1.54
Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol (2007) 1.52
Hospitalizations during pregnancy among managed care enrollees. Obstet Gynecol (2002) 1.50
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn (2011) 1.48
The variability of urinary protein and creatinine excretion in patients with gestational proteinuric hypertension. Br J Obstet Gynaecol (1992) 1.46
The role of observer error in antenatal dipstick proteinuria analysis. Br J Obstet Gynaecol (1999) 1.45
Long-term mortality after preeclampsia. Epidemiology (2005) 1.44
Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered (2006) 1.41
Pregnancy-associated hospitalizations in the United States, 1999-2000. Am J Obstet Gynecol (2005) 1.39
Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol (2007) 1.34
Barbados Low Dose Aspirin Study in Pregnancy (BLASP): a randomised trial for the prevention of pre-eclampsia and its complications. Br J Obstet Gynaecol (1998) 1.33
Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol (2000) 1.30
Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG (2006) 1.29
Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol (2007) 1.29
Estimation of proteinuria as a predictor of complications of pre-eclampsia: a systematic review. BMC Med (2009) 1.27
Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol (2005) 1.26
Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol (2008) 1.26
Toll-like receptor 4: a potential link between "danger signals," the innate immune system, and preeclampsia? Am J Obstet Gynecol (2005) 1.26
Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy (2007) 1.25
Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS One (2010) 1.25
Maternal and perinatal outcome in pregnancies complicated with hypertensive disorder of pregnancy: a seven year experience of a tertiary care center. Arch Gynecol Obstet (2005) 1.24
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med (2009) 1.24
The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol (2010) 1.23
Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia. Am J Obstet Gynecol (2001) 1.23
Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol (2010) 1.22
Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Biol Reprod (1994) 1.20
Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol (2006) 1.20
Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol (2007) 1.20
Vitamin C supplementation in pregnancy. Cochrane Database Syst Rev (2005) 1.18
Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol (2006) 1.16
Circulating angiogenic factors and placental abruption. Obstet Gynecol (2006) 1.15
Serum inhibin A and angiogenic factor levels in pregnancies with previous preeclampsia and/or chronic hypertension: are they useful markers for prediction of subsequent preeclampsia? Am J Obstet Gynecol (2008) 1.14
Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension (2007) 1.13
Apoptosis cascade progresses during turnover of human trophoblast: analysis of villous cytotrophoblast and syncytial fragments in vitro. Lab Invest (1999) 1.12
Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J Matern Fetal Neonatal Med (2005) 1.12
Pre-eclampsia and expression of heparin-binding EGF-like growth factor. Lancet (2002) 1.11
Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet Gynecol (2008) 1.10
Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol (1998) 1.10
Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.10
Predictive value of angiogenic factors and uterine artery Doppler for early- versus late-onset pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol (2008) 1.09
Emerging roles of antiangiogenic and angiogenic proteins in pathogenesis and prediction of preeclampsia. Hypertension (2007) 1.09
Epidemiology and causes of preterm birth. Lancet (2008) 18.96
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
A systems biology approach for pathway level analysis. Genome Res (2007) 6.95
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
The role of inflammation and infection in preterm birth. Semin Reprod Med (2007) 3.57
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01
Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol (2011) 2.95
Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet (2008) 2.90
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med (2006) 2.59
Machine learning and its applications to biology. PLoS Comput Biol (2007) 2.57
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42
The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36
The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. Microbiome (2014) 2.24
Listeriosis in human pregnancy: a systematic review. J Perinat Med (2011) 2.20
The role of cervical cerclage in obstetric practice: can the patient who could benefit from this procedure be identified? Am J Obstet Gynecol (2006) 2.11
Diabetes prevalence and determinants in adults in China mainland from 2000 to 2010: a systematic review. Diabetes Res Clin Pract (2012) 2.07
Inflammation in pregnancy: its roles in reproductive physiology, obstetrical complications, and fetal injury. Nutr Rev (2007) 2.01
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med (2005) 1.99
Evolution of the mammalian placenta revealed by phylogenetic analysis. Proc Natl Acad Sci U S A (2006) 1.89
Genomics, biogeography, and the diversification of placental mammals. Proc Natl Acad Sci U S A (2007) 1.86
CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
A sonographic short cervix as the only clinical manifestation of intra-amniotic infection. J Perinat Med (2006) 1.82
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol (2004) 1.81
Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery. J Matern Fetal Neonatal Med (2010) 1.77
Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol (2010) 1.77
Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol (2009) 1.77
Identification of fetal and maternal single nucleotide polymorphisms in candidate genes that predispose to spontaneous preterm labor with intact membranes. Am J Obstet Gynecol (2010) 1.75
Prevalence and diversity of microbes in the amniotic fluid, the fetal inflammatory response, and pregnancy outcome in women with preterm pre-labor rupture of membranes. Am J Reprod Immunol (2010) 1.74
Human spontaneous labor without histologic chorioamnionitis is characterized by an acute inflammation gene expression signature. Am J Obstet Gynecol (2006) 1.73
Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.69
Gene-centric genomewide association study via entropy. Genetics (2008) 1.68
Nifedipine in the management of preterm labor: a systematic review and metaanalysis. Am J Obstet Gynecol (2011) 1.65
Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol (2004) 1.64
A short cervix in women with preterm labor and intact membranes: a risk factor for microbial invasion of the amniotic cavity. Am J Obstet Gynecol (2005) 1.64
Antibiotic administration to patients with preterm premature rupture of membranes does not eradicate intra-amniotic infection. J Matern Fetal Neonatal Med (2007) 1.62
Clinical significance of intra-amniotic inflammation in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (2004) 1.60
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Intrauterine endotoxin administration leads to white matter diffusivity changes in newborn rabbits. J Child Neurol (2009) 1.58
Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol (2002) 1.58
Structural and functional comparison of mast cells in the pregnant versus nonpregnant human uterus. Am J Obstet Gynecol (2006) 1.54
The clinical significance of a positive Amnisure test in women with term labor with intact membranes. J Matern Fetal Neonatal Med (2009) 1.54
A systematic approach to the use of the multiplanar display in evaluation of abnormal vascular connections to the fetal heart using 4-dimensional ultrasonography. J Ultrasound Med (2007) 1.53
The ninety-fifth percentile for growth discordance predicts complications of twin pregnancy. Am J Obstet Gynecol (2002) 1.53
Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol (2006) 1.53
Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol (2004) 1.51
Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol (2009) 1.50
The evolution of menstruation: a new model for genetic assimilation: explaining molecular origins of maternal responses to fetal invasiveness. Bioessays (2011) 1.50
The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med (2008) 1.50
Toll-like receptor-2 and -4 in the chorioamniotic membranes in spontaneous labor at term and in preterm parturition that are associated with chorioamnionitis. Am J Obstet Gynecol (2004) 1.49
The prognosis of pregnancy conceived despite the presence of an intrauterine device (IUD). J Perinat Med (2010) 1.48
A randomized trial of amnioreduction versus septostomy in the treatment of twin-twin transfusion syndrome. Am J Obstet Gynecol (2005) 1.48
Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol (2007) 1.47
The risk of impending preterm delivery in asymptomatic patients with a nonmeasurable cervical length in the second trimester. Am J Obstet Gynecol (2010) 1.45
A single nucleotide polymorphism in the matrix metalloproteinase-1 (MMP-1) promoter influences amnion cell MMP-1 expression and risk for preterm premature rupture of the fetal membranes. J Biol Chem (2001) 1.42
A comparison of gene set analysis methods in terms of sensitivity, prioritization and specificity. PLoS One (2013) 1.41
Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered (2006) 1.41
Strengths and limitations of microarray-based phenotype prediction: lessons learned from the IMPROVER Diagnostic Signature Challenge. Bioinformatics (2013) 1.39
Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol (2010) 1.39
The clinical significance of detecting Ureaplasma urealyticum by the polymerase chain reaction in the amniotic fluid of patients with preterm labor. Am J Obstet Gynecol (2003) 1.38
TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. J Immunol (2009) 1.37
The transcriptome of the fetal inflammatory response syndrome. Am J Reprod Immunol (2010) 1.37
Detection of a microbial biofilm in intraamniotic infection. Am J Obstet Gynecol (2008) 1.37
Intrauterine administration of endotoxin leads to motor deficits in a rabbit model: a link between prenatal infection and cerebral palsy. Am J Obstet Gynecol (2008) 1.36
Functionally significant SNP MMP8 promoter haplotypes and preterm premature rupture of membranes (PPROM). Hum Mol Genet (2004) 1.35
N-acetylcysteine reduces lipopolysaccharide-sensitized hypoxic-ischemic brain injury. Ann Neurol (2007) 1.33
A novel molecular microbiologic technique for the rapid diagnosis of microbial invasion of the amniotic cavity and intra-amniotic infection in preterm labor with intact membranes. Am J Reprod Immunol (2014) 1.32